Cocrystal PharmaCOCP -3.35%25 EBITDA Margin % is -1,041.78% as of Mar. 2026. GuruFocus rates COCP with a GF Score™ of 25/100. The stock has 3 warning signs investors should review. Among 945 Biotechnology companies, Cocrystal Pharma ranks worse than 88.47% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Cocrystal Pharma's EBITDA for the
three
months ended in Mar. 2026 was $-2.34 Mil. Cocrystal Pharma's Revenue for the
three
months ended in Mar. 2026 was $0.23 Mil. Therefore, Cocrystal Pharma's EBITDA margin for the quarter that ended in Mar. 2026 was -1,041.78%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Cocrystal Pharma EBITDA Margin % Related Terms
Cocrystal Pharma EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Cocrystal Pharma's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
COCP vs OSRH, CVKD, LEXX: EBITDA Margin % Comparison
For the Biotechnology subindustry, Cocrystal Pharma's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cocrystal Pharma EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cocrystal Pharma's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Cocrystal Pharma's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cocrystal Pharma (COCP) has a EBITDA Margin % of -1,041.78% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Cocrystal Pharma and its competitors. According to the industry distribution chart, Cocrystal Pharma ranks #836 out of 945 companies in the Biotechnology industry, placing it in the top 88.5%.
Is Cocrystal Pharma's EBITDA Margin % too high?
Cocrystal Pharma's current EBITDA Margin % is -1,041.78%. Based on the distribution chart, Cocrystal Pharma ranks #836 out of 945 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Cocrystal Pharma has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does Cocrystal Pharma's EBITDA Margin % compare to OSRH and CVKD?
According to the Biotechnology industry distribution chart, Cocrystal Pharma ranks #836 out of 945 companies for EBITDA Margin %. This places Cocrystal Pharma in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Cocrystal Pharma and its competitors. Cocrystal Pharma's current EBITDA Margin % is -1,041.78%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cocrystal Pharma stock overvalued right now?
Cocrystal Pharma (COCP) has a current EBITDA Margin % of -1,041.78%. The current EBITDA Margin % is -1,041.78%. Cocrystal Pharma's overall GF Score™ is 25/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Cocrystal Pharma (COCP), the current EBITDA Margin % is -1,041.78% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first and in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI). The company has one reportable and operating segment dedicated to the research and development company's novel orally administered antiviral influenza candidate. The company has pipeline products for diseases like : Influenza, Norovirus, Coronavirus, Respiratory Viruses, and Hepatitis C.
25GF Score
Get the complete analysis for COCP
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
COCP has been successfully added to your 
